Key Highlights

• FDA Regulatory Acceptance for Sarepta: The FDA accepted supplemental applications for Sarepta's Duchenne treatments, setting a clear PDUFA timeline.

• Pivotal Trial Initiation for Candel: Candel Therapeutics began its global pivotal Phase 3 AURORA trial in advanced lung cancer patients.

• Early Enrollment Completion for 4D Molecular: 4D Molecular Therapeutics completed Phase 3 enrollment four months ahead of schedule.

Multiple biotech names posted significant clinical and regulatory milestones in late June 2026, collectively illustrating the breadth of positive catalyst activity across the clinical-stage and commercial biotech landscape during this period.

Sarepta Therapeutics (NASDAQ: SRPT) saw FDA acceptance of supplemental applications for its Duchenne treatments Amondys 45 and Vyondys 53, setting a clear regulatory timeline with a PDUFA target action date of February 28, 2027.

Candel Therapeutics (NASDAQ: CADL) initiated its pivotal Phase 3 AURORA trial in lung cancer, a major clinical development milestone supported by extensive global trial infrastructure spanning more than 150 sites with overall survival as the primary endpoint.

4D Molecular Therapeutics (NASDAQ: FDMT) completed Phase 3 enrollment four months ahead of schedule for its wet AMD program, demonstrating strong operational execution that reinforced investor confidence in the company's clinical development capabilities.

Together, these catalysts reflect a broader healthcare sector rotation as capital moved from richly valued tech into clinical-stage biotech with near-term data readouts, as investors increasingly sought exposure to companies with concrete, near-term value-creating milestones.

()